Home Alzheimer’s Disease Belantamab Mafodotin Triplet Yields Promising Clinical Benefit in Relapsed/Refractory Multiple Myeloma

Belantamab Mafodotin Triplet Yields Promising Clinical Benefit in Relapsed/Refractory Multiple Myeloma

The combination use of belantamab mafodotin plus bortezomib (Velcade) and dexamethasone (B-Vd) induced high clinical benefit rates and a tolerable safety profile in patients with relapsed or refractory multiple myeloma, according to preliminary findings from a cohort of the phase 1/2 DREAMM-6 trial.1

“Preliminary data for the 18 patients who have received belantamab mafodotin 2.5 mg/kg single dosing with bortezomib/dexamethasone suggests that this combination has an acceptable safety profile with no new safety signals identified,” said Ajay K. Nooka, MD, MPH, FACP, associate professor in the Department of Hematology and Medical Oncology, Emory University School of Medicine, in a prerecorded presentation of the early findings for the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program. “Clinical response looks promising,” he added.

The objective…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Cause of Alzheimer’s disease traced to mutation in common enzyme

submitted by /u/scotsman81 Continue Reading to the Source

Reflections on Living With an Incurable Illness : braincancer

(I’ve checked with the moderators to make sure this is appropriate and a good fit for this subreddit. I'm a very private person, and...

This Foramen Magnum Meningioma almost killed me 18 years ago.

submitted by /u/dkrem Continue Reading to the Source

Recent Comments